Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA) have received an average recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have covered the stock in the last year is $42.75.

KLRA has been the subject of several recent analyst reports. TD Cowen initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday. They set a “buy” rating and a $57.00 price objective for the company. Evercore started coverage on shares of Kailera Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. Leerink Partners initiated coverage on shares of Kailera Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $36.00 price target for the company. William Blair initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. assumed coverage on Kailera Therapeutics in a report on Tuesday. They set an “overweight” rating and a $30.00 price objective on the stock.

Kailera Therapeutics Stock Up 0.0%

KLRA traded up $0.01 on Tuesday, reaching $22.94. The company’s stock had a trading volume of 61,974 shares, compared to its average volume of 850,625. Kailera Therapeutics has a fifty-two week low of $20.86 and a fifty-two week high of $28.23.

Insider Activity at Kailera Therapeutics

In other news, Director Andrew T. Kaplan bought 8,398,438 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average cost of $16.00 per share, with a total value of $134,375,008.00. Following the transaction, the director directly owned 26,255,581 shares in the company, valued at $420,089,296. This trade represents a 47.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Rtw Investments, Lp purchased 500,000 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $8,000,000.00. Following the purchase, the insider directly owned 10,776,820 shares in the company, valued at $172,429,120. The trade was a 4.87% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 10,460,938 shares of company stock valued at $167,375,008 in the last three months.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.